GSK3B

1GNG, 1H8F, 1I09, 1J1B, 1J1C, 1O6K, 1O6L, 1O9U, 1PYX, 1Q3D, 1Q3W, 1Q41, 1Q4L, 1Q5K, 1R0E, 1UV5, 2JDO, 2JDR, 2JLD, 2O5K, 2OW3, 2UW9, 2X39, 2XH5, 3CQU, 3CQW, 3DU8, 3E87, 3E88, 3E8D, 3F7Z, 3F88, 3GB2, 3I4B, 3L1S, 3M1S, 3MV5, 3OW4, 3PUP, 3Q3B, 3QKK, 3SAY, 3SD0, 3ZDI, 3ZRK, 3ZRL, 3ZRM, 4ACC, 4ACD, 4ACG, 4ACH, 4AFJ, 4B7T, 4DIT, 4EKK, 4IQ6, 4J1R, 4J71, 4NM0, 4NM3, 4NM5, 4NM7, 4PTC, 4PTE, 4PTG, 5F94, 5F95, 5HLP, 5HLN293256637ENSG00000082701ENSMUSG00000022812P49841Q9WV60NM_001146156NM_002093NM_001354596NM_019827NM_001347232NP_001139628NP_002084NP_001341525NP_001334161NP_062801Glycogen synthase kinase 3 beta, also known as GSK3B, is an enzyme that in humans is encoded by the GSK3B gene. In mice, the enzyme is encoded by the GSK-3β gene. Abnormal regulation and expression of GSK3β is associated with an increased susceptibility towards bipolar disorder.1gng: GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE1h8f: GLYCOGEN SYNTHASE KINASE 3 BETA.1i09: STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)1j1b: Binary complex structure of human tau protein kinase I with AMPPNP1j1c: Binary complex structure of human tau protein kinase I with ADP1o9u: GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE1pyx: GSK-3 Beta complexed with AMP-PNP1q3d: GSK-3 Beta complexed with Staurosporine1q3w: GSK-3 Beta complexed with Alsterpaullone1q41: GSK-3 Beta complexed with Indirubin-3'-monoxime1q4l: GSK-3 Beta complexed with Inhibitor I-51q5k: crystal structure of Glycogen synthase kinase 3 in complexed with inhibitor1r0e: Glycogen synthase kinase-3 beta in complex with 3-indolyl-4-arylmaleimide inhibitor1uv5: GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH 6-BROMOINDIRUBIN-3'-OXIME Glycogen synthase kinase 3 beta, also known as GSK3B, is an enzyme that in humans is encoded by the GSK3B gene. In mice, the enzyme is encoded by the GSK-3β gene. Abnormal regulation and expression of GSK3β is associated with an increased susceptibility towards bipolar disorder. Glycogen synthase kinase-3 (GSK-3) is a proline-directed serine-threonine kinase that was initially identified as a phosphorylating and an inactivating agent of glycogen synthase. Two isoforms, alpha (GSK3A) and beta, show a high degree of amino acid homology. GSK3B is involved in energy metabolism, neuronal cell development, and body pattern formation. It might be a new therapeutic target for ischemic stroke. Homozygous disruption of the GSK-3β locus in mice results in embryonic lethality during mid-gestation. This lethality phenotype could be rescued by inhibition of tumor necrosis factor. Two SNPs at this gene, rs334558 (-50T/C) and rs3755557 (-1727A/T), are associated with efficacy of lithium treatment in bipolar disorder. Pharmacological inhibition of ERK1/2 restores GSK3β activity and protein synthesis levels in a model of tuberous sclerosis. GSK3B has been shown to interact with: